hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06300632, orgStudyIdInfo id: Geriatric Locomotive Syndrome, briefTitle: Geriatric Locomotive Syndrome and Related Factors in Older Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Kırıkkale University, class: OTHER, descriptionModule briefSummary: It has been stated that the results of physical function and physical performance affecting locomotive syndrome in elderly individuals are controversial and studies are still needed. However, no studies have been found examining its relationship with the decrease in physical activity level, decline in cognitive functions, kinesiophobia (fear of movement) and fatigue seen in old age. Early detection of locomotive syndrome risk factors in elderly individuals will help prevent this condition, detect the risk of falling in elderly individuals and increase their quality of life. Based on these deficiencies, it is aimed to examine the relationship between locomotive syndrome and kinesiophobia, physical activity level, physical performance, fatigue and cognitive functions in elderly individuals., conditionsModule conditions: Locomotive Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 97, type: ESTIMATED, armsInterventionsModule interventions name: geriatric locomotive syndrome, outcomesModule primaryOutcomes measure: Geriatric Locomotive Function Scale, primaryOutcomes measure: Two Step Test, primaryOutcomes measure: Stand Up Test, primaryOutcomes measure: Tampa Kinesiophobia Scale, primaryOutcomes measure: Physical Activity Scale for the Elderly (PASE), primaryOutcomes measure: Short Physical Performance Battery, primaryOutcomes measure: Fatigue Severity Scale, primaryOutcomes measure: Montreal Cognitive Assessment Scale (MoCA), eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ayşe Abit Kocaman, status: RECRUITING, city: Kırıkkale, country: Turkey, contacts name: Ayşe Abit Kocaman, Asst. Prof., role: CONTACT, phone: +90318-357 37 38 / 4700, email: ayseabit@gmail.com, geoPoint lat: 39.84528, lon: 33.50639, hasResults: False
protocolSection identificationModule nctId: NCT06300606, orgStudyIdInfo id: NOL1 and RA, briefTitle: Nociception Index Level (NOL) Perioperative Monitoring During Regional Anesthesia, acronym: NOL and LRA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: American Hospital of Paris, class: OTHER, collaborators name: Nataliya KARASHCHUK, collaborators name: Briana LUI, collaborators name: Thierry GUENOUN, collaborators name: Stephane ROMANO, descriptionModule briefSummary: This prospective observational study was conducted to assess pain using NOL index under locoregional anesthesia for orthopedic surgery of the upper limb. We included 50 consecutive adult patients scheduled for orthopedic surgery of the upper limb under locoregional anesthesia. The locoregional anesthesia was performed under ultrasound, with or without neurostimulation. Intraoperative pain is assessed using NOL index monitoring, ALGISCORE and Numerical Scale, and second point study is the midazolam and propofol requirement., conditionsModule conditions: Regional Anesthesia, conditions: Pain, conditions: Intraoperative Monitoring, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: NOL monitoring, outcomesModule primaryOutcomes measure: pain score, primaryOutcomes measure: pain score, secondaryOutcomes measure: sedative requirement, secondaryOutcomes measure: anxiolytic requirement, secondaryOutcomes measure: failure of regional anesthesia, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gilles BOCCARA, status: RECRUITING, city: Neuilly-sur-Seine, zip: 92200, country: France, contacts name: Gilles BOCCARA, role: CONTACT, phone: +33662382833, email: gilles.boccara@ahparis.org, contacts name: thierry GUENOUN, role: CONTACT, phone: +33146412691, email: thierry.guenoun@ahparis.org, geoPoint lat: 48.8846, lon: 2.26965, hasResults: False
protocolSection identificationModule nctId: NCT06300580, orgStudyIdInfo id: M23-991, briefTitle: Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-03, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: AbbVie, class: INDUSTRY, descriptionModule briefSummary: The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer \[11C\]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.ABBV-932 is a dopamine D3 receptor-preferring D3/D2 receptor partial agonist. Approximately 12 adult healthy volunteers will be enrolled in the United Kingdom.Participants will receive ABBV-932 oral capsules once daily for 2 weeks and followed for 60 days.Participants will be confined for approximately 15 days. Participants will receive 3 \[11C\]-(+)-PHNO PET scans during the study. Adverse Events and blood tests will be performed., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: ABBV-932, outcomesModule primaryOutcomes measure: Change in Dopamine Receptor Occupancy in Brain Measured by Positron Emission Tomography (PET), primaryOutcomes measure: Number of Participants with Adverse Events (AEs), eligibilityModule sex: ALL, minimumAge: 23 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06300567, orgStudyIdInfo id: CFTR-RD misdiagnosis, briefTitle: Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-02, completionDateStruct date: 2026-11-02, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Hôpital Necker-Enfants Malades, class: OTHER, descriptionModule briefSummary: Assessment of the outcome of patients not concluded fir cystic fibrosis, either symptomatic patients or asymptomatic children detected by newborn screening for cystic fibrosis. The aim is to identify patients potentially at risk of progressing to the clinical spectrum of cystic fibrosis, conditionsModule conditions: CFTR-RD, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: data collection, outcomesModule primaryOutcomes measure: lung Imaging, secondaryOutcomes measure: lung infection, secondaryOutcomes measure: pancreatic function, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06300554, orgStudyIdInfo id: 2023-1653, secondaryIdInfos id: A171600, type: OTHER, domain: UW Madison, secondaryIdInfos id: Version 1/26/2024, type: OTHER, domain: UW Madison, briefTitle: 10th Mountain Healthy Minds Program App Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, descriptionModule briefSummary: The purpose of the study is to evaluate the acceptability, feasibility, and preliminary effects of the Healthy Minds Program (HMP) App in approximately 150 active duty military members., conditionsModule conditions: Well-Being, Psychological, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Healthy Minds Program App, outcomesModule primaryOutcomes measure: System Usability Scale Score, primaryOutcomes measure: Acceptability of Intervention Measure (AIM), primaryOutcomes measure: Intervention Appropriateness Measure (IAM), primaryOutcomes measure: Feasibility of Intervention Measure (FIM), primaryOutcomes measure: HMP App Usage: Did you use the Healthy Minds Program App (Yes or No), primaryOutcomes measure: HMP App Usage: Did you download the Healthy Minds Program App (Yes or No), secondaryOutcomes measure: Change in Perceived Stress Score, secondaryOutcomes measure: Change in WHO-5 Well-Being Score, secondaryOutcomes measure: Change in PROMIS Depression Score, secondaryOutcomes measure: Change in PROMIS Anxiety Score, secondaryOutcomes measure: Change in Meaning of Life Questionnaire - Presence Subscale Score, secondaryOutcomes measure: Change in NIH Toolbox Loneliness Score, secondaryOutcomes measure: Change in Suicide Cognitions Scale Score, secondaryOutcomes measure: HMP App Usage: How many times did you use the HMP App, otherOutcomes measure: HMP App Usage: Reasons for not downloading the HMP App, otherOutcomes measure: HMP App Usage: Reasons for not opening the HMP App, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Wisconsin, city: Madison, state: Wisconsin, zip: 53705, country: United States, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06300528, orgStudyIdInfo id: OSU-23423, secondaryIdInfos id: NCI-2024-01530, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), briefTitle: Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Narendranath Epperla, class: OTHER, descriptionModule briefSummary: This phase II trial tests how well pemigatinib works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Pemigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth., conditionsModule conditions: Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, conditions: Recurrent Mantle Cell Lymphoma, conditions: Recurrent Marginal Zone Lymphoma, conditions: Recurrent Nodal Marginal Zone Lymphoma, conditions: Recurrent Splenic Marginal Zone Lymphoma, conditions: Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, conditions: Refractory Mantle Cell Lymphoma, conditions: Refractory Marginal Zone Lymphoma, conditions: Refractory Nodal Marginal Zone Lymphoma, conditions: Refractory Splenic Marginal Zone Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Bone Marrow Aspiration, interventions name: Bone Marrow Biopsy, interventions name: Computed Tomography, interventions name: Pemigatinib, interventions name: Positron Emission Tomography, outcomesModule primaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Complete response (CR) rate, secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Incidence of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio State University Comprehensive Cancer Center, city: Columbus, state: Ohio, zip: 43210, country: United States, contacts name: Narendranath Epperla, MD, MS, role: CONTACT, phone: 614-393-3196, contacts name: Narendranath Epperla, MD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06300502, orgStudyIdInfo id: 2023P003620, briefTitle: Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: Johns Hopkins University, descriptionModule briefSummary: This study will evaluate the tolerability and effectiveness of four FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, and Kybella and Polidocanol injections. Each patient will have a treatment and a control site.This study is designed with the goal of improved efficacy/tumor reduction via multiple treatment visits. If there is minimal to no clinical improvement in tumor size with one treatment after three treatment visits, the subject will be given the option of crossover treatment with the most effective of the four treatments. Three treatment visits with the crossover treatment will then take place., conditionsModule conditions: Neurofibromas, Cutaneous, conditions: Neurofibromatosis 1, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Kybella, interventions name: Asclera, interventions name: 755nm Alexandrite Laser, interventions name: 1064nm Nd:YAG Laser, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], secondaryOutcomes measure: Numeric Rating Scale (NRS-11)/Patient Satisfaction, secondaryOutcomes measure: Skindex 16, secondaryOutcomes measure: Patient Reported Outcomes, secondaryOutcomes measure: Clinician Reported Outcomes, otherOutcomes measure: Rate of healing, otherOutcomes measure: cNF appearance (volume), otherOutcomes measure: cNF appearance (height), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wellman Center for Photomedicine, city: Boston, state: Massachusetts, zip: 02114, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06300489, orgStudyIdInfo id: CARTOnG-2401, briefTitle: Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-03, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Zhejiang Cancer Hospital, class: OTHER, descriptionModule briefSummary: This study is a multicenter, open, and phase I dose increasing clinical study. Based on the UGT1A1 \* 28 and \* 6 genotypes of patients with locally advanced rectal cancer, determine the dose limiting toxicity (DLT) and maximum tolerable dose (MTD) of weekly irinotecan liposomes in concurrent chemoradiotherapy with capecitabine, investigate the tolerance of irinotecan liposome combined with capecitabine in concurrent chemoradiotherapy with locally advanced rectal cancer, and recommend the dosage for Phase II clinical study，and explore the pharmacokinetic characteristics of irinotecan liposomes combined with capecitabine.At the same time，Preliminary observe the efficacy and safety of irinotecan liposomes combined with capecitabine in chemoradiotherapy.The study plans to recruit 30 patients with advanced rectal cancer who have not received any therapy., conditionsModule conditions: Rectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: irinotecan liposomes+capecitabine, outcomesModule primaryOutcomes measure: DLT（dose-limiting toxicity）, primaryOutcomes measure: MTD（maximum tolerable dose）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, country: China, contacts name: Ji Zhu, role: CONTACT, phone: 0571-88128152, email: leo.zhu@126.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06300476, orgStudyIdInfo id: 2023-1511, briefTitle: Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-20, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2029-12-30, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: West China Hospital, class: OTHER, descriptionModule briefSummary: The purpose of the study is to assess the safety and efficacy of JWK006 in Stargardt Disease(STGD1).JWK006 is packed by adeno-associated virus vector that expressing ABCA4 gene., conditionsModule conditions: Stargardt Disease 1, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: JWK006, outcomesModule primaryOutcomes measure: Safety(Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events), secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Ophthalmoscope Measurement, secondaryOutcomes measure: Qualitative and quantitative assessments of autofluorescence pattern (FAF), secondaryOutcomes measure: multifocal electroretinogram (mfERG), eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: West China Hospital, city: Chengdu, state: Sichuan, zip: 610044, country: China, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06300463, orgStudyIdInfo id: 23-06026214, briefTitle: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Weill Medical College of Cornell University, class: OTHER, collaborators name: Agenus Inc., descriptionModule briefSummary: The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are:* whether these combinations of immunotherapy change the tumor microenvironment in the liver* whether these combinations of immunotherapy are safe and effective when used in colorectal cancer with liver metastasesParticipants will be randomly assigned to one of the following:* Botensilimab and balstilimab* Botensilimab, balstilimab, and AGEN1423* Botensilimab, balstilimab, and radiationParticipants will be asked to come in to receive drug infusions (and radiation, if applicable) before and after their surgical resection. Participants will be followed for up to 2 years., conditionsModule conditions: Colorectal Cancer Metastatic, conditions: Liver Metastases, conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Botensilimab, interventions name: Balstilimab, interventions name: AGEN1423, interventions name: Radiation, outcomesModule primaryOutcomes measure: Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm, secondaryOutcomes measure: Number of Treatment-Related Adverse Events (TRAEs) as assessed by CTCAE v5.0 per treatment arm, secondaryOutcomes measure: Pathological Response Rate Per Arm, secondaryOutcomes measure: Radiographic Response Rate Per Arm, secondaryOutcomes measure: Number of Participants Per Arm with ctDNA Clearance, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Weill Cornell Medicine/NewYork-Presbyterian Hospital, status: RECRUITING, city: New York, state: New York, zip: 10065, country: United States, contacts name: Casey Owens, role: CONTACT, phone: 646-962-8189, email: cdo4001@med.cornell.edu, contacts name: Myriam Elizaire-Williams, role: CONTACT, email: mye4001@med.cornell.edu, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False